🟢 Rezolute is trading 5.8% up with no clear company-specific catalyst

Rezolute is trading up 5.76% at $4.04 on October 27, 2026; no new company-specific announcement was found to explain the move.

• On October 14, Rezolute reported completing enrollment in its Phase 3 upLIFT study, with topline results expected in mid-December.
• Biotech shares were stronger, with XBI up 2.18% during the regular session; this may provide industry context but does not establish a specific cause for Rezolute’s larger gain.